<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02352311</url>
  </required_header>
  <id_info>
    <org_study_id>DK-DT-002</org_study_id>
    <nct_id>NCT02352311</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetic Characteristics of DKF-313</brief_title>
  <official_title>A Randomized, Open-label, Single-dose, 2-treatment, 2-way, 2-period Crossover Study to Evaluate the Safety and the Pharmacokinetic Characteristics of DKF-313 in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dongkook Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dongkook Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, open-label, single-dose, 2-treatment, 2-way, 2-period crossover study
      to evaluate the safety and the pharmacokinetic characteristics of DKF-313 (dutasteride and
      tadalafil) in healthy male volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is conducted to evaluate the pharmacokinetics of DKF-313 (dutasteride and
      tadalafil) comparing with the concomitant administration of AVODART and CIALIS in healthy
      male volunteers.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUClast and Cmax of dutasteride and tadalafil</measure>
    <time_frame>0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144, 192 h</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Benign Prostate Hyperplasia</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Arm 1 AVODART, CIALIS, DKF-313</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Period 1, AVODART (dutasteride) soft gelatin capsule and CIALIS (tadalafil) tablet 5 mg are administered as single dose. In Period 2, DKF-313 tablet (dutasteride 0.5 mg and tadalafil 5 mg) is administered as single dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2 DKF-313, AVODART, CIALIS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Period 1, DKF-313 tablet (dutasteride 0.5 mg and tadalafil 5 mg) is administered as single dose. In Period 2, AVODART (dutasteride) soft gelatin capsule and CIALIS (tadalafil) tablet 5 mg are administered as single dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DKF-313</intervention_name>
    <description>Combination of dutasteride 0.5 mg and tadalafil 5 mg</description>
    <arm_group_label>Arm 1 AVODART, CIALIS, DKF-313</arm_group_label>
    <arm_group_label>Arm 2 DKF-313, AVODART, CIALIS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AVODART</intervention_name>
    <description>Dutasteride 0.5 mg</description>
    <arm_group_label>Arm 1 AVODART, CIALIS, DKF-313</arm_group_label>
    <arm_group_label>Arm 2 DKF-313, AVODART, CIALIS</arm_group_label>
    <other_name>Dutasteride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CIALIS</intervention_name>
    <description>Tadalafil 5 mg</description>
    <arm_group_label>Arm 1 AVODART, CIALIS, DKF-313</arm_group_label>
    <arm_group_label>Arm 2 DKF-313, AVODART, CIALIS</arm_group_label>
    <other_name>Tadalafil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 19 to 29 years

          2. BMI 17.5 to 30.5 kg/m2 and body weight 55 kg or more

          3. No congenital or chronic diseases within 3 years, no disease symptoms or findings

          4. Eligible according to the laboratory results of hematology, blood chemistry and
             urinalysis and ECG

          5. Voluntarily signed the informed consent form 6. Willing to participate in the study

        Exclusion Criteria:

          1. Clinically significant disorders of blood, kidney, endocrine, respiratory system,
             gastrointestinal system, urology, cardiovascular system, liver, psychiatry, neurology
             or allergy

          2. Gastrointestinal diseases or surgery which may affect absorption of the
             investigational products

          3. ALT or AST &gt; 2xULN

          4. Excessive alcohol consumption (&gt; 210 g/week) within 6 months

          5. Participated and administered the investigational products in other clinical trial
             within 2 months

          6. SBP ≤ 100 mmHg or ≥ 150 mmHg or DBP ≤ 60 mmHg or ≥ 100 mmHg

          7. History or positive result of serious alcohol or drug abuse within 1 year

          8. Drugs which induce or inhibit drug metabolism within 1 month

          9. Smoked more than 10 cigarettes a day

         10. Prescribed drugs or over-the counter drugs within 10 days

         11. Donated whole blood within 2 months or apheresis within 1 month

         12. Severe acute/chronic medical and mental conditions or lab abnormalities which may
             increase the risk or interfere in the interpretation of study results

         13. Hypersensitivity to tadalafil or phosphodiesterase type 5 inhibitor, and dutasteride
             or 5-α reductase inhibitor, or other drugs including aspirin, antibiotics, etc.

         14. Galactose intolerance, fructose intolerance, Lapp lactase deficiency,
             glucose-galactose malabsorption

         15. CYP3A4 inhibitors or CYP3A4 inducers within 2 weeks

         16. Myocardial infarction within 90 days

         17. Unstable angina or angina during sexual intercourse

         18. Heart failure (New York Heart Association Class 2 or higher) within 6 months

         19. Uncontrolled arrhythmias

         20. Stroke within 6 months

         21. Inherited retinal degeneration including retinitis pigmentosa

         22. Vision loss in one eye due to non-arteritic anterior ischemic optic neuropathy (NAION)

         23. Plans to donate blood for at least 6 months after final dose of the investigational
             products

         24. Unwilling to comply with the lifestyle guidelines in the protocol

         25. Not eligible due to other reasons at the investigator's discretion
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>29 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Min-Gul Kim, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chonbuk National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Min-Gul Kim, M.D.</last_name>
    <phone>+82-63-250-1487</phone>
    <email>mgkim@jbctc.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chonbuk National University Hospital</name>
      <address>
        <city>Jeonju</city>
        <state>Jeollabuk-do</state>
        <zip>561-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Min-Gul Kim, M.D.</last_name>
      <phone>+82-63-250-1487</phone>
      <email>mgkim@jbctc.org</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 22, 2015</study_first_submitted>
  <study_first_submitted_qc>January 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2015</study_first_posted>
  <last_update_submitted>February 1, 2015</last_update_submitted>
  <last_update_submitted_qc>February 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Prostatic Hyperplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tadalafil</mesh_term>
    <mesh_term>Dutasteride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

